1-5 of 5
impulse-control disorder
Close
Sort by
Journal Articles

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Francis K. Buadi, MB, CHB, Martha Q. Lacy, MD, Betsy Laplant, MS, Eric Wolfe, Morie A. Gertz, MD, Sikander Ailawadhi, MD, Suzanne R. Hayman, MD, Ronald S. Go, MD, Dania Kaehlyn Helgeson, Vivek Roy, MD, Craig B. Reeder, MD, Amie Fonder, PA-C, MS, Yi L. Hwa, APRN, CNP, DNP, Miriam A. Hobbs, APRN, CNP, DNP, P. Leif Bergsagel, MD, Rafael Fonseca, MD, David Dingli, MD PhD, Wilson I Gonsalves, MD, Prashant Kapoor, MD, Asher A. Chanan-Khan, MD, Taxiarchis Kourelis, MD, Jeremy Larsen, Stephen J Russell, MD PhD, John A. Lust, MD PhD, Taimur Sher, MD, Mustaqeem A. Siddiqui, MDMBA, A. Keith Stewart, MB, ChB, Rahma M Warsame, MD, S. Vincent Rajkumar, MD, Robert A. Kyle, MD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1904.
https://doi.org/10.1182/blood-2019-131478
Published: 2019
Journal Articles

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Alessandra Larocca, Paolo Corradini, Roberto Mina, Nicola Cascavilla, Anna Marina Liberati, Norbert Pescosta, Maria Teresa Petrucci, Giovannino Ciccone, Andrea Capra, Francesca Patriarca, Delia Rota Scalabrini, Vanessa Innao, Marco Poggiu, Michele Cea, Renato Zambello, Anna Baraldi, Angelo Belotti, Claudia Cellini, Monica Galli, Mariella Grasso, Sara Aquino, Gloria Margiotta Casaluci, Giovanni De Sabbata, Stelvio Ballanti, Massimo Offidani, Katia Mancuso, Mario Boccadoro, Sara Bringhen
Journal: Blood
Blood (2019) 134 (Supplement_1): 3195.
https://doi.org/10.1182/blood-2019-124388
Published: 2019
Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 902.
https://doi.org/10.1182/blood.V130.Suppl_1.902.902
Published: 2017
Journal Articles

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Shaji Kumar, MD, Norbert Grzasko, MD PhD, Sosana Delimpasi, MD, Wieslaw W Jędrzejczak, MD, Sebastian Grosicki, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Andrew Spencer, Neeraj Gupta, PhD, Zhaoyang Teng, PhD, Catriona Byrne, RN, Richard Labotka, MD MS, Meletios A Dimopoulos
Journal: Blood
Blood (2016) 128 (22): 3327.
https://doi.org/10.1182/blood.V128.22.3327.3327
Published: 2016
Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD
Journal: Blood
Blood (2015) 126 (23): 26.
https://doi.org/10.1182/blood.V126.23.26.26
Published: 2015